Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein

CD44H is the principal cell surface receptor for hyaluronate, which is a major glycosaminoglycan of the extracellular matrix. Expression of CD44H is enhanced in a variety of malignant tumors and correlates with tumor aggressiveness, supporting the notion that interaction between CD44H and hyaluronat...

Descripción completa

Detalles Bibliográficos
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 1992
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2119319/
https://www.ncbi.nlm.nih.gov/pubmed/1500863
_version_ 1782141232381689856
collection PubMed
description CD44H is the principal cell surface receptor for hyaluronate, which is a major glycosaminoglycan of the extracellular matrix. Expression of CD44H is enhanced in a variety of malignant tumors and correlates with tumor aggressiveness, supporting the notion that interaction between CD44H and hyaluronate may play an important role in tumor growth and dissemination. In this report we show that in vivo tumor formation by human lymphoma Namalwa cells, stably transfected with CD44H, can be suppressed by a soluble human CD44H-immunoglobulin fusion protein. Disruption of the interaction between CD44H and its physiologic ligands may provide a novel strategy for controlling tumor growth in vivo.
format Text
id pubmed-2119319
institution National Center for Biotechnology Information
language English
publishDate 1992
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21193192008-04-16 Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein J Exp Med Articles CD44H is the principal cell surface receptor for hyaluronate, which is a major glycosaminoglycan of the extracellular matrix. Expression of CD44H is enhanced in a variety of malignant tumors and correlates with tumor aggressiveness, supporting the notion that interaction between CD44H and hyaluronate may play an important role in tumor growth and dissemination. In this report we show that in vivo tumor formation by human lymphoma Namalwa cells, stably transfected with CD44H, can be suppressed by a soluble human CD44H-immunoglobulin fusion protein. Disruption of the interaction between CD44H and its physiologic ligands may provide a novel strategy for controlling tumor growth in vivo. The Rockefeller University Press 1992-08-01 /pmc/articles/PMC2119319/ /pubmed/1500863 Text en This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Articles
Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein
title Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein
title_full Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein
title_fullStr Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein
title_full_unstemmed Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein
title_short Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein
title_sort inhibition of tumor growth in vivo with a soluble cd44-immunoglobulin fusion protein
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2119319/
https://www.ncbi.nlm.nih.gov/pubmed/1500863

Ejemplares similares